Skip to content
  • info@qps.com
  • English
    • Chinese (Simplified)
qps-30-logo-144ppi
  • Company
  • Locations
    • USA
      • Delaware
      • Miami
      • Missouri
    • Europe
      • The Netherlands
      • Austria
    • Taiwan
      • CTPS
      • NKSP
      • Qualitix
    • India
  • Insights
Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt
  • Services
      Bioanalysis >
      • Assay Finder
      • Biomarkers and Translational Medicine
      • Biotherapeutics
      • Cell and Gene Therapy
      • CLIA
      • Genomics
      • ICP-MS (Mass Spectrometry)
      • Small Molecules
      Preclinical Services >
      • DMPK
      • Biotransformation
      • Micro Autoradiography (MARG)
      • Preclinical DDI Studies
      • Protein Binding
      • Radiolabeled ADME
      • Quantitative Whole-Body Autoradiography (QWBA)
      • IND Package
      • Pharmacology
      • Toxicology
      Lab Services >
      • Leukopak Services
      • Peripheral Blood Mononuclear Cells (PBMCs)
      Clinical Services >
      • Early Stage Clinical Trials
      • Clinical Research Services
      • Project Management and Site Monitoring
      • Site Identification and Qualification
      • Global Medical Affairs
      • Medical Writing Services
      • Pharmacovigilance
      • Global Regulatory Affairs
      • Central Safety Lab
      • Clinical Trial Kits
      • Clinical Biostatistics Consultancy
      • Clinical Data Management
      • Study Recruitment
  • Resources
    • Our Science
      • Expert Interviews
      • Podcasts
      • Scientific Posters
      • Scientific Reference Articles
      • Thought Leadership
      • Webinars
      • White Papers
    • Our Expertise
      • Dermatology
        • Dermal and Transdermal
      • Endocrinology
      • Inflammatory Bowel Disease
      • Neuropsychiatry
      • Obesity Clinical Trials
      • Oncology Clinical Trials
      • Rheumatology
      • Vaccines
      • Women’s Health
    • Services Materials
      • Brochures
        • Brochures – Chinese
        • Brochures – Japanese
        • Brochures – Korean
      • Case Studies
      • eBooks
      • Ultimate Guides
        • Oncology
        • Oligonucleotides
        • Gene Therapy
      • Videos
    • Guidance Documents
  • Blog
    • Infographics
  • Careers
  • Contact
QPS Logo
qps-30-logo-144ppi
  • Company
  • Locations
    • USA
      • Delaware
      • Miami
      • Missouri
    • Europe
      • The Netherlands
      • Austria
    • Taiwan
      • CTPS
      • NKSP
      • Qualitix
    • India
  • Insights
  • Services
    • Bioanalysis
      • Assay Finder
      • Biomarkers and Translational Medicine
      • Biotherapeutics
      • Cell and Gene Therapy
      • CLIA
      • Genomics
      • ICP-MS (Mass Spectrometry)
      • Small Molecules
    • Preclinical Services
      • DMPK
        • Biotransformation
        • Micro Autoradiography (MARG)
        • Preclinical DDI Studies
        • Protein Binding
        • Radiolabeled ADME
        • Quantitative Whole-Body Autoradiography (QWBA)
      • IND Package
      • Pharmacology
      • Toxicology
    • Lab Services
      • Leukopak Services
      • Peripheral Blood Mononuclear Cells (PBMCs)
    • Clinical Services
      • Early Stage Clinical Services
      • Clinical Research Services
        • Project Management and Site Monitoring
        • Site Identification and Qualification
        • Global Medical Affairs
          • Medical Writing Services
          • Pharmacovigilance
        • Global Regulatory Affairs
        • Central Safety Lab
        • Clinical Trials Kits
        • Clinical Biostatistics Consultancy
        • Clinical Data Management
        • Study Recruitment
  • Resources
    • Our Science
      • Expert Interviews
      • Podcasts
      • Scientific Posters
      • Scientific Articles
      • Thought Leadership
      • Webinars
      • White Papers
    • Our Expertise
      • Dermatology
        • Dermal and Transdermal
      • Endocrinology
      • Inflammatory Bowel Disease
      • Neuropsychiatry
      • Obesity Clinical Trials
      • Oncology Clinical Trials
      • Rheumatology
      • Vaccines
      • Women’s Health
    • Service Materials
      • Brochures
        • Brochures – Chinese
        • Brochures – Japanese
        • Brochures – Korean
      • Case Studies
      • eBooks
      • Ultimate Guides
        • Oncology
        • Oligonucleotides
        • Gene Therapy
      • Videos
    • Guidance Documents
  • Blog
    • Blog Infographics
  • Careers
  • Contact

Cell and Gene Therapy

Home / Cell and Gene Therapy
QPS-logo-white-tagline

Over 800 Assays Available

download-ios
download-google

Cell and Gene Therapy

Home / Cell and Gene Therapy
QPS-logo-white-tagline

Gene Therapy And Cell Therapy​

Oligonucleotide-based therapy (antisense RNAs, aptamers, siRNAs, miRNAs, mRNAs, vectors) is receiving a great deal of attention. As a gene therapy CRO, QPS has supported cell and gene therapy product development since 2003 on 45+ ASO/siRNA/aptamers and 20+ mRNA/vectors programs and can use our hard-earned experience to help you navigate PK, immunogenicity, biodistribution, viral clearance, and ADME properties of these novel modalities in this rapidly expanding field.

As this is still a relatively new area, the preferred technology for the quantitation of oligonucleotide-based therapy in any biological matrix is not as well-defined as small organics or proteins and vaccines. QPS uses chromatographic, ligand binding, and QPCR methods for quantitation of oligonucleotide-based therapy. The choice of platform for detection and quantitation is based on the primary structure of the target, the number of monomeric units, the desired study design, and the comfort level of the sponsors with the various platforms.

Additional Resources

  • The Ultimate Guide to Gene Therapy
  • Oligonucleotides
  • Leukopak Services
  • Global Medical Affairs
  • Global Regulatory Affairs
  • Peripheral Blood Mononuclear Cells (PBMCs)

QPS is ready to work with you to determine specific study parameters and provide complete, fully-compliant data packages and reports, ready for submission.

Oligonucleotides Quantitation By Hybridization Plus Ligand Binding

Depending on the nature of the oligonucleotide therapy, we may instead employ a probe-hybridization followed by ligand binding with ELISA using colorimetric, fluorescent, chemiluminescent detection as well as Gyrolab®, and MSD® approach. We found the hybridization-MSD approach particularly useful for ocular indication where we have developed and validated multiple “single mixed-matrices” assays to quantitate oligonucleotides in all the target tissues.

Oligonucleotides

Oligonucleotides Quantitation By High-Resolution Mass Spectrometry Or Hybridization Plus Chromatography

For chromatographic methods, since 2003 we have used the traditional triple quadrupole LC MS/MS, as well as LC/UV assays to examine plasma and tissues exposure.

Since 2014, our method of choice for quantitation of double stranded (ds) oligonucleotides is UPLC-ToF-MS. This high-resolution (UPLC-HRMS) methodology can simultaneously determine both the sense and the anti-sense strands using a “N in 1” approach where the “N”s are the exact mass of the individual isotopic peaks of the different charge envelopes. We have quantitated up to 20,000 Daltons ds oligonucleotides with LLOQ at 5 ng/mL per the latest FDA Bioanalytical Method Validation guidance. With the current state-of-the-art UPLC HRMS that we just installed we will be working at the sub-ng/mL LLOQ.

The real power of HRMS is in the use full scan mode vs. the traditional MRM mode. Full scan data means each sample can be mined for metabolite information in the true qual-quan fashion. This provides the drug developer a clear understanding of the metabolism of the individual strand within each tissue investigated, in parallel with plasma PK and tissue PK. On the flip side, the ‘price’ for this high data density is a batch run of three 96-well plates is close to 5GB. This becomes prohibitive if the facility lacks a well-tuned proper intra-structure.

Depending on the nature of the oligonucleotide drug, we may instead employ a probe-hybridization approach. QPS designs complementary fluorescence-tagged probes to track the antisense strand or other relevant portion of the modality. The fluorescence-tagged antisense drug and “N-1, N-2, N-3,…” length reference metabolites are assessed by LC FLD in a single run allowing both the parent drug and its metabolites to be distinguished and quantitated. Additionally, QPS has experience with PEGylated aptamers, which are best studied using LC-UV assay systems for quantitation.

Oligo DNA Strand

mRNA Therapeutic And Gene Therapy Vector Quantitation by qPCR

Vectors such as adeno-associated viruses (AAV) lentivirus, and glycoprotein of the lymphocytic choriomeningitis virus (VSV-GP), and nucleic acid drug targets that are long enough and offer sufficient sequence complexity are quantitated using real-time, quantitative PCR (typically probe hydrolysis) with reverse-transcription, if necessary.

These assays are custom built that include usually the sequences of the transgene as well as the specific vectors to detect only your drug target, while additional assays can be developed to assess secondary targets or drug response or biodistribution or shedding. Multiple automated extraction devices and microfluidic plate assembly robots are used for high throughput production. The staff have years of nucleic acid assay design and quantitation in regulated environments.

In parallel, ADA assay will need to be developed for the vectors. To address the PK and immunogenicity respond of the vector and the translated protein/enzyme.

DNA-in-blue-vials

Links to Relevant Documents

  • Five Criteria to Use When Selecting a CRO for a Gene Therapy Study
  • Regulated Bioanalysis of Antibody Drug Conjugates
  • Immunogenicity Overview
  • Biomarker Capabilities
  • Biomarkers and Translational Medicine
  • Alphabetic Assay List
  • Drug Assay List
  • Biochemical Biomarker Assay List
  • Genomic Biomarker Assay 

Leadership

Linkedin-in

Monique Putman, Ph.D.

Competency Director, Translational Medicine
Linkedin-in

Monique Putman, Ph.D.

Competency Director, Translational Medicine
Linkedin-in

Susan Zondlo, Ph.D.

Sr. Director, Translational Medicine
Linkedin-in

Susan Zondlo, Ph.D.

Sr. Director, Translational Medicine
Linkedin-in

Xun Wang, Ph.D.

Sr. Director, Translational Medicine
Linkedin-in

Xun Wang, Ph.D.

Sr. Director, Translational Medicine
Linkedin-in

Rick Hamler

Associate Director, Bioanalysis
Linkedin-in

Rick Hamler

Associate Director, Bioanalysis

Testimonials

Yes, good to see such close repeats; overall, confirms that the up/down patterns were “real” and that the assay is performing well. Again, thanks to Jerry and, especially, Angel for the extra effort; much appreciated!
CHRIS P.
Thank you so much for providing the data file at such short notice. I really appreciate all your help with this.
KELLY K.
We would like to pass along our kudos to all involved in making this happen. We are thankful to you for the partnership, as it has been instrumental in achieving our milestones.
QPS CLIENT, Director of Clinical Operations
Yes, good to see such close repeats; overall, confirms that the up/down patterns were “real” and that the assay is performing well. Again, thanks to Jerry and, especially, Angel for the extra effort; much appreciated!
CHRIS P.
Thank you so much for providing the data file at such short notice. I really appreciate all your help with this.
KELLY K.
We would like to pass along our kudos to all involved in making this happen. We are thankful to you for the partnership, as it has been instrumental in achieving our milestones.
QPS CLIENT, Director of Clinical Operations
Yes, good to see such close repeats; overall, confirms that the up/down patterns were “real” and that the assay is performing well. Again, thanks to Jerry and, especially, Angel for the extra effort; much appreciated!
CHRIS P.

Time is of the essence in Drug Development.

Contact the QPS Business Development Team Today!

Your link to a rewarding career.

Join the QPS team and be part of our growing organization.

Submit Your Resume

About qps

  • Mission, Vision, and Values
  • QPS History
  • Bioanalysis Milestones
  • Locations
  • Meet Our People
  • Blog
  • Careers
  • Privacy Policy
  • Mission, Vision, and Values
  • QPS History
  • Bioanalysis Milestones
  • Locations
  • Meet Our People
  • Blog
  • Careers
  • Privacy Policy

Preclinical Services

  • Assay Finder
  • DMPK
  • IND Package
  • Pharmacology
  • Toxicology
  • Assay Finder
  • DMPK
  • IND Package
  • Pharmacology
  • Toxicology

Clinical Services

  • Early Phase Clinical Trials
  • Leukopak Services
  • Global Medical Affairs
  • Global Regulatory Affairs
  • Therapeutic Areas
  • Early Phase Clinical Trials
  • Leukopak Services
  • Global Medical Affairs
  • Global Regulatory Affairs
  • Therapeutic Areas

Resources

  • Brochures
  • Case Studies
  • Conferences
  • eBooks
  • Guidance Documents
  • Milestones
  • Scientific Posters
  • Scientific Reference Articles
  • Thought Leadership
  • Videos/Webinars
  • White Papers
  • Brochures
  • Case Studies
  • Conferences
  • eBooks
  • Guidance Documents
  • Milestones
  • Scientific Posters
  • Scientific Reference Articles
  • Thought Leadership
  • Videos/Webinars
  • White Papers

Headquarters Location

Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711

  • +1 512 350 2827
  • +1 302 369 5601, option 0
  • info@qps.com
  • Sales: +1 512 350 2827
  • HQ: +1 302 369 5601, option 0
  • info@qps.com

Connect with us

Linkedin-in Youtube Facebook-f Instagram
download-ios
download-google
qps-assay-finder-black

Subscribe To Our Blog

"*" indicates required fields

Name
Address
Confirmation*
This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.

Copyright © 2025 · QPS Holdings. All Rights Reserved | Web Design by 417 Marketing.
Contact Us
Scroll to Top

Notifications